Business Context and Reporting Period
Company: BioCardia, Inc. (BCDA)
Filing Type: Form 8-K (Current Report)
Date of Report: April 2, 2026
Reporting Period: Event-based report for activities occurring on April 2, 2026.
Key Financial Metrics
This filing is a regulatory disclosure regarding a corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material event reported is the submission of clinical study data to the United States Food and Drug Administration (FDA). Specifically, BioCardia submitted data from the CardiAMP HF clinical study. Additionally, the company announced plans to meet with the FDA to discuss the accelerated approval pathway for the CardiAMP® System, which is intended for the treatment of ischemic chronic heart failure with reduced ejection fraction (HFrEF).
Guidance, Outlook, and Risks
Management Commentary: The company is actively pursuing regulatory approval for its CardiAMP® System via an accelerated pathway following the submission of the CardiAMP HF study data.
Risks and Contingencies: The filing does not explicitly detail new risks or contingencies beyond the inherent uncertainty of FDA regulatory review processes. The press release attached as Exhibit 99.1 contains the full details of the submission but is not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the specific contents and results of the CardiAMP HF clinical study data submitted to the FDA.
- Confirm the scheduled date and agenda for the upcoming meeting with the FDA regarding the accelerated approval pathway.
- Review the attached press release (Exhibit 99.1) for detailed clinical endpoints and management's specific expectations for the regulatory timeline.
- Monitor subsequent filings for any FDA responses or requests for additional information.